Lingying Wu

16PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 12, 2026
Lactate-Induced ZMYM2 K529 Lactylation Stabilizes ZMYM2 and Promotes Platinum Resistance in Ovarian Cancer.

|Jun 02, 2026
Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives.

|Mar 20, 2026
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

Herui Yao, Min Yan, Zhongsheng Tong

|Feb 27, 2026
MMHC-OCPR: Prediction of Platinum Response and Recurrence Risk in Ovarian Cancer with Multimodal Deep Learning.

Enyu Tang, Haoming Xia, Zhenlong Yuan

|Jan 09, 2026
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

Guangwen Yuan, Ge Lou, Jundong Li

|Jul 24, 2024
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.

Jing Zuo, Wei Duan, Mingxuan Zhao

Pageof 3

Frequent Collaborators

3 joint publications

Ning Li

2 joint publications

Zhenlong Yuan

2 joint publications

Enyu Tang

2 joint publications

Qi Zhou